Form 4: Inhibrx Biosciences Director Reports Acquisition of Shares and Stock Options Following Sanofi Merger

Director Jon Faiz Kayyem reports acquiring shares and stock options in Inhibrx Biosciences following the distribution of shares related to the merger with Sanofi.

Summary

• Jon Faiz Kayyem, a director of Inhibrx Biosciences, filed a Form 4 detailing changes in beneficial ownership.
• The report covers transactions occurring on May 29, 2024, related to the distribution of Inhibrx Biosciences shares to Inhibrx, Inc. shareholders after the Sanofi merger.
• Kayyem acquired 806,075 shares of common stock indirectly through The Jon F. Kayyem and Paige Gates-Kayyem Family Trust.
• He also acquired 6,250 shares each for the benefit of two minor children, Child A and Child B, held in custodial accounts.
• Additionally, Kayyem acquired a stock option to purchase 30,000 shares of common stock at an exercise price of $15.86, granted following the merger with Sanofi.
• The stock option vests fully on May 30, 2025, contingent upon continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to a corporate transaction. The acquisition of shares by a director is mildly positive, but the document itself is primarily informational.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects following the merger with Sanofi.
• The granting of stock options to management aligns their interests with those of shareholders.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of stock options contingent on continued service suggests an expectation of ongoing involvement by the reporting person.

Industry Context

Following the merger of Inhibrx, Inc. with a Sanofi subsidiary, this Form 4 filing reflects the resulting distribution of Inhibrx Biosciences shares and the granting of stock options, which is a common practice in such transactions to incentivize management.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry, often used to align management incentives with shareholder value creation.
• The vesting schedule of the options, contingent on continued service, is also a typical arrangement.
• Comparable companies like Regeneron, Amgen, and Gilead Sciences also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive sign.
• Employees may be affected by the vesting of stock options, incentivizing continued service.

Key Dates